Naegleriafowleri is an etiologic agent of primary amoebic meningoencephalitis in humans and laboratory animals (4) . We observed recently that repeated small doses of cyclophosphamide (CPA) protected mice from primary amoebic meningoencephalitis, although a single large dose of CPA administered before challenge with N. fowleri neither protected from the amoeba nor reduced host resistance (15) .
CPA is used as an immunosuppressive agent for treating autoimmune diseases and for preventing graft rejection (1) . Numerous investigators, however, have demonstrated that, when administered in low doses before or soon after antigen exposure, CPA enhances the cellular and humoral immune responses (2, 7, 9, 11, 12, 14) . The effects of CPA on the immune system are known to be mediated by CPA metabolites rather than by the parent compound (5) . The cytochrome P-450 monooxygenase system converts CPA to 4-hydroxy-cyclophosphamide, which rearranges to aldophosphamide. Aldophosphamide undergoes beta elimination to release acrolein and the alkylating compound phosphoramide mustard (6, 16) . Recent studies by Kawabata and White (8) have demonstrated that administration of acrolein to mice 1 day before sensitization enhanced delayed-type hypersensitivity and antibody-forming-cell responses to sheep erythrocytes to an extent similar to that obtained with CPA treatment. Because the chemotherapy for primary amoebic meningoencephalitis is not satisfactory (10) , CPA and acrolein were tested for antiamoebic activity. The growth of N. fowleri exposed to CPA and acrolein in vitro was observed, as well' as the effects on host resistance. The results indicated that acrolein and not CPA is the antiamoebic agent.
MATERIALS AND METHODS N. fowleri LEE was isolated from a patient who died of primary amoebic meningoencephalitis in 1968 (19) ; strain LEE has been propagated axenically in Nelson medium since then (18) . Strain LEE is only moderately pathogenic for mice. N. fowleri LEEmp was derived by serial passage of strain LEE in mice and isolation from the brains of moribund mice. The mouse-passaged strain is highly pathogenic. N. fowleri LEE and LEEmp were harvested from axenic cultures in Nelson medium (15) and were diluted to 105 amoebae per ml before being dispensed into a 24-well plate (0.9 ml per well).
Sendai virus-free female B6C3F1 mice were purchased To determine whether a metabolite of CPA was responsible for the antiamoebic activity, mice were treated with phenobarbital (80 mg/kg i.p.) daily for 4 days to induce higher levels of mixed-function oxidase activities. Mice were bled by cardiac puncture 4 h after administration of CPA (200 mg/kg) intravenously (i.v.). The blood was allowed to clot; the serum was collected after centrifugation at 2,000 x g for 10 min and heated at 56°C for 30 min. Next, 0.1 ml of serum was added to 0.9 ml of Nelson medium inoculated with N. fowleri (105/ml; LEE or LEEmp). Sera from mice not treated with phenobarbital served as the control.
To determine whether acrolein was amoebicidal, a culture of N. fowleri LEE was prepared at a concentration of 106 amoebae per ml of Nelson medium containing different concentrations of acrolein: 40, 8, or 1.6 ,uM. One group was incubated at 5°C; the other group was incubated at 37°C. After 1 h of incubation, the medium was replaced by new drug-free Nelson medium. The cultures were then incubated at 37°C, and the amoebae were counted at 48 and 96 h. To determine whether growth conditions were required for amoebicidal activity, N. fowleri LEE was starved overnight in Page saline (19) . Page saline containing different concentrations of acrolein was added, and the cultures were incubated at 37°C for 1 h. Next, the drug-containing Page saline was replaced with Nelson medium. The cultures were incubated at 370C, and the amoebae were counted at 48 and 96 h. N. fowleri is an amoeboflagellate that transforms from an amoeba into a flagellate when subcultured from nutrient medium into a nonnutrient medium. To assess the effect of acrolein on enflagellation, N. fowleri LEE and LEEmp from stationary-phase cultures were harvested and rinsed twice with Page saline in 25-cm2 tissue culture flasks. The flasks containing 10 ml of 106 amoebae per ml of cell suspension were placed upright in a gyratory shaking water bath (New Brunswick Scientific Co., New Brunswick, N.J.) at 37°C for 4 to 6 h to induce inflagellation (19) . Acrolein was added to a final concentration of 40, 8, or 1.6 ,uM. The number of amoeboid and elongated flagellated cells in a total population of at least 100 cells was ascertained with a light microscope every hour for 4 h. A group without acrolein served as control.
RESULTS
Mice treated i.p. with a single dose of 200 mg of CPA per kg 2 days before challenge were neither more nor less h. Growth inhibition was as severe after exposure to acrolein for 1 h as with continuous exposure (Table 3) . Most of the antiamoebic activity was lost after 1 h of incubation with acrolein at 5 or 37°C in culture medium containing serum or Page saline (data not shown).
Starving amoebae were injured by acrolein at a concentration of 40 ,M and were partly inhibited at a concentration of 8 ,uM. Amoebae incubated with acrolein at 5°C for 1 h were also injured ( Table 4) . Enflagellation of N. fowleri LEE and LEEmp was prevented by acrolein at a concentration of 40 ,uM, markedly inhibited at a concentration of 8 ,uM, and slightly inhibited at a concentration of 1.6 ,uM (Fig. 1) .
Acrolein administered as a single dose of 100 ,umol/kg i.v. on the day of challenge did not protect mice infected with N. fowleri. Acrolein given at 50 pumol/kg i.v. starting 2 days before challenge and continued daily for 5 days protected mice infected with N. fowleri (Table 5) .
DISCUSSION
It is well established that acrolein is one of the metabolites of CPA in vivo (6, 16) . Acrolein has been shown previously to inhibit the growth of eucaryotic (3) and procaryotic (17) cells. Acrolein shows antiamoebic activity in vivo and in vitro and is probably responsible for the protection afforded by CPA against primary amoebic meningoencephalitis. Phosphoramide mustard, another metabolite of CPA (16) , is much less cytotoxic than acrolein for splenocytes (8) and for N. fowleri.
CPA administered daily afforded protection against infection by N. fowleri. This regimen actually impairs the immune response and host resistance (13) ; therefore, a chemotherapeutic action is the most likely cause of the protection. The observed protection may reflect chemoprophylaxis or treatment of primary amoebic meningoencephalitis or both. Serum from CPA-treated mice did not inhibit growth of amoebae, but the antiamoebic product acrolein is quite unstable. A dose of 30 mg of CPA per kg is capable of generating acrolein equivalent to 107 ,mollkg. It is not readily possible to duplicate in vitro the in vivo generation of acrolein from daily doses of CPA. Acrolein is quite toxic, and the therapeutic index (toxic dose/therapeutic dose ratio) is smaller than is generally considered acceptable (4 versus 10). It is unlikely that acrolein itself can be used therapeutically, but a chemical derivative of acrolein may possess more-favorable therapeutic potential.
Acrolein is amoebicidal and leads to cells lysis at higher concentrations. Acrolein inhibits starving amoebae and chilled amoebae, indicating a direct action of acrolein rather than an action mediated by cell metabolism. Acrolein inhibits enflagellation of sublethal concentrations, indicating that the drug can inhibit a critical process in enflagellation:
polyribonucleotide synthesis or protein synthesis. Acrolein is known to bind readily to sulfhydryl groups of important cellular macromolecules (6, 8) . Acrolein suppresses the antibody-forming-cell response of murine splenocytes (8) and enflagellation by N. fowleri at concentrations which do not markedly decrease cell viability. Damage to the plasma membrane, causing loss of selective permeability, would account for the observed effects of acrolein.
